AstraZeneca presents new clinical data at the 2020 ASCO Virtual Scientific Program
By AstraZeneca | Jun 4, 2020
AstraZeneca presented new clinical data from its Phase 1a study with AZD4635, a next-generation immuno-oncology candidate, as a monotherapy and in combination with the PD-L1 antibody durvalumab (Imfinzi), in patients with advanced prostate cancer, at the 2020 ASCO Virtual Scientific Program (29-31 May 2020).
AZD4635 is a oral inhibitor of adenosine 2A receptor (A2AR) signaling discovered by Sosei Heptares and exclusively licensed to AstraZeneca in 2015.
Adenosine signaling is a normal process preventing autoimmunity that is co-opted by tumors as an immune escape mechanism. Pharmacologic blockade of signaling through A2aR may counteract the immunosuppressive effects of adenosine and allow for a more robust anti-tumor immune response in combination with immune checkpoint inhibitors.
The poster (abstract #5518) was entitled “A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary anti-tumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: results from prostate cancer patients (NCT02740985),” and reported the following: